XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.22

-5.0%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (8566)	2/1/1999 3:55:00 PM
From: Bluegreen	Read Replies (2) of 17367

George, do you think this last offering was done as part of anticipating approval of Neuprex? How many batches of Neuprex can you make for 12 million? FROM THE COMPANY:>>>>>>>Do you have an estimated date that the Neuprex(tm) data will go to the FDA for final review? (6/98) The meningococcemia Phase III trial is scheduled to complete enrollment at the end of 1998. The earliest we will know results is after the 90-day follow-up period. Assuming the data are positive, we would complete the BLA (Biologics License Application) filing to FDA most likely by midyear. Once you apply, how long will it take the FDA to approve? (6/98) A rare and frequently fatal children's disease will probably receive close FDA attention. We will continue to pursue available fast-track options with FDA and European agencies.<<<<<<<<<<<<<<< As you see from above Xoma says "probably will receive close FDA attention". What does that mean George? How is the 12 million tied into all of this and how come Peter Davis picked august, 1999 in regard to the offering? Does he expect something positive by then? STAY TUNED! DON'T TOUCH THAT DIAL! AS THE STOMACH TURNS!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next